Volume Spikes After YM BioSciences Reports Updated Phase III Data; Endocyte plunges on drug study results Print E-mail
By Staff and Wire Reports   
Tuesday, 13 December 2011 19:17
Below is a look at some of the headlines for companies that made news in the healthcare sector on December 13, 2011.

YM BioSciences Inc. (NYSE:YMI)
, reported updated results from the ongoing Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The results are being presented this evening in a poster session at the 53rd Annual Meeting of the American Society of Hematology underway in San Diego, CA.

"In this multicenter study, CYT387 continues to demonstrate a unique ability to render and maintain myelofibrosis patients transfusion independent for clinically-relevant periods, while also producing significant and durable improvements in their splenomegaly and constitutional symptoms," said Dr. Nick Glover, President and CEO of YM BioSciences. "In addition, MRI results obtained from a subset of subjects confirm the meaningful improvements in splenomegaly as measured by palpation. Moreover, CYT387 was well tolerated, with dosing up to and exceeding two years."

"While additional assessments and analyses are ongoing across dose levels, 300 mg/day appears to be a safe and effective dosing regimen that warrants further clinical development," added Dr. Glover. "We look forward to leveraging these data to advance our regulatory strategy and our business development activities with the goal of starting pivotal trials in mid-2012."

Phase I/II Study Updated Results - The Core Phase I/II study has completed enrollment of 166 myelofibrosis patients across six study sites. The Core study consists of nine 28-day treatment cycles where CYT387 is orally self-administered, primarily at dosages of 150 mg once-daily (QD), 300 mg QD or 150 mg twice-daily (BID). Patients who tolerate and benefit from the drug may continue to receive CYT387 beyond the Core study in an Extension phase. While data collection and analysis are ongoing, preliminary safety and efficacy results from this multicenter study are presented below.

Subject Characteristics - The majority of the 166 patients enrolled have Primary Myelofibrosis (65%); 22% have Post-Polycythemia vera and 14% have Post-Essential thrombocythemia. Other patient characteristics include:  DIPSS-Plus category: Int-1 - 11%; Int-2 - 61%; High - 28% -- JAK2V617F positive: 76% -- Red blood cell transfusion-dependent: 44% -- Palpable splenomegaly >10 cm: 80%.  

The trial also enrolled patients who had received previous therapies, including other JAK inhibitors (12%) and IMiDs (9%).

Subject Disposition - The median follow-up time for patients in the Core study and Extension phase is 10.4 months (range: 0.8-25.6 months; ongoing). To date, 97% of patients who have completed the Core study have continued into the Extension phase. During the Core study, 32 patients (19%) have discontinued the study, five for possibly or probably related adverse events, for a current overall retention rate of 81%. The retention rate during the Extension phase is currently 79%.

Anemia Response - Of the 68 patients who were transfusion dependent at baseline, to date 54% have become transfusion independent for a minimum of 12 weeks. The median duration of the transfusion-free period has not yet been reached (range: 82-506 days, ongoing). More than 25% of subjects who were not receiving transfusions while on study experienced at least a 1 g/dL increase in hemoglobin lasting for more than eight weeks.

Of the 26 patients who were dosed at 300mg QD and were transfusion dependent at baseline, to date 65% have become transfusion independent for a minimum of 12 weeks.

Spleen Response - Of the 142 patients evaluable for spleen response, 31% achieved a response per IWG-MRT*. The median duration of spleen response has not yet been reached (range: 55 - 574 days, ongoing). The median time to spleen response was 15 days (range: 6 - 260 days, ongoing). To date, 49% of patients achieved more than a 50% maximal decrease in spleen size from baseline, with 87% achieving more than a 25% maximal decrease.

Of the 51 patients who were dosed at 300mg QD and were evaluable for spleen response, 33% achieved a response per IWG-MRT.

Eleven patients were evaluable for spleen response both by MRI and by palpation. The response rate was 64% by MRI (defined as a 35% decrease in spleen volume) and 45% by palpation (defined as a 50% decrease in spleen length). The median splenic decrease from baseline at three months was -41% by volume measured by MRI and -45% by length measured by palpation.

*International Working Group for Myelofibrosis Research and Treatment

Constitutional Symptoms Response - The majority of patients reporting constitutional symptoms at baseline demonstrated a Complete Resolution or Marked Improvement of their symptoms, including night sweats, pruritus and bone pain.

Safety Results - CYT387 is well tolerated in myelofibrosis patients for dosing periods up to and exceeding two years. Reported adverse effects include thrombocytopenia; transient, mild dizziness; mild peripheral neuropathy; and abnormalities in liver/pancreas-related laboratory tests. Treatment emergent anemia and neutropenia were rarely reported.

Poster presentation and YM conference call:  The updated results from the Phase I/II study will be presented in a poster session at the 53rd Annual Meeting of the American Society of Hematology. Poster #3849, entitled "Safety and Efficacy of CYT387, a JAK1 and JAK2 Inhibitor for the Treatment of Myelofibrosis", will be presented at Session #634, Myeloproliferative Syndromes: Poster III, being held on Monday, December 12th from 6:00-8:00pm PT in Hall GH of the San Diego Convention Center.


Shares of Endocyte Inc. (NASDAQ:ECYT) +1.96% plunged 63% to $3.85 after it released disappointing results from supplemental analyses of a Phase II clinical trial for its cancer therapy EC145. Endocyte has been testing the compound in conjunction with other cancer-fighting agents in women with platinum-resistant ovarian cancer. The analyses showed that EC145 did not help patients live longer.

Also Tuesday:

Coronado Biosciences, Inc., (OTCBB: CNDO)
, a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that an oral presentation on CNDO-109 was given at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition held at the San Diego Convention Center in California.

ICU Medical, Inc. (NASDAQ: ICUI)
announced that a clinical study presented at the American Society of Nephrology's (ASN) Kidney Week 2011 showed the Tego® needlefree hemodialysis connector can decrease heparin use and reduce costs for dialysis clinics.

InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV)
, a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that CEO Frank Reynolds is scheduled to appear on WBAL-TV’s Sunday morning newscast on December 18th during their 8:00 AM (Eastern Time) newscast.

Landec Corporation (NASDAQ:LNDC)
announced today that it will report financial results for the fiscal year 2012 second quarter ended November 27, 2011, after market close on Tuesday, January 3, 2012.

Marijuana, Inc. (PINKSHEETS: HEMP)
is proud to announce the first event covered by MarijuanaIncTV LIVE as its film crew documented The Art of Mary Jane Magazine/Cash Hyde Foundation well attended Fundraiser held at actor and filmmaker Sean Cook's Bel Air, California estate, on Saturday, Dec. 10, 2011.

Rainbow Coral Corp. (OTCBB:RBCC)
today announced that it is in the process of becoming a member of the life science research group BioHouston.

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating the ability to permanently correct a disease gene in an adult mouse model of hemophilia B using systemic delivery of zinc finger nucleases (ZFNs) at the 53nd Annual Meeting of the American Society of Hematology (ASH).

Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502), today announced interim results from a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed advanced stage Hodgkin lymphoma patients.

Synergy Pharmaceuticals, Inc. (Nasdaq: SGYPD, SGYPU)
, a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has filed a lawsuit in New York State Supreme Court against Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie.

Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, today announced that new data from the Company's Neo-Urinary Conduit™ (NUC) and Neo-Kidney Augment™ (NUC) programs are featured in several presentations at the TERMIS North America Annual Conference being held December 11-14, in Houston, TX.

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Megapharm Ltd., one of Israel's leading private biotech, pharmaceutical and medical nutrition marketing companies, for the commercialization of Fanapt™  in Israel.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus